

Atty Docket No. PC27820A
 Appl. No. 10/815,589
 Reply to Office action of February 12, 2007

RECEIVED
 CENTRAL FAX CENTER
 MAY 07 2007


Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the above-identified application.

Listing of Claims:

Claims 1-38 (cancelled)

39 (new). A compound of formula I:



or a pharmaceutically acceptable salts thereof;

wherein Y is $-\text{SO}_m-$, $-\text{O}-$, or $-\text{N}(\text{R}^8)-$;

Z is $\text{C}(=\text{Q})\text{R}^1$, $-\text{NHC}(=\text{Q})\text{R}^1$, $-\text{C}(=\text{Q})\text{NHR}^1$, $-\text{NHC}(=\text{NCN})\text{R}^1$, $-\text{NHC}(=\text{NNO}_2)\text{R}^1$, $-\text{SO}_2\text{R}^1$, or $-\text{NH}_2$;

Q is oxygen or sulfur atom;

R^1 -H, OH, $-\text{NH}_2$, $-\text{NHC}_{1-4}\text{alkyl}$, $-\text{C}_{1-4}\text{alkyl}$, $-\text{C}_{2-4}\text{alkenyl}$, $-(\text{CH}_2)_p\text{C}(=\text{O})\text{C}_{1-4}\text{alkyl}$, $-\text{OC}_{1-4}\text{alkyl}$, $-\text{SC}_{1-4}\text{alkyl}$, $-(\text{CH}_2)_p\text{C}_{3-6}\text{cycloalkyl}$, $-\text{CH}=\text{CH-aryl}$, or $\text{CH}_2\text{C}(=\text{O})\text{-aryl}$;

R^2 and R^3 are independently -H, or -F;

R^4 and R^5 are independently -H, -Cl, -F, -CH₃, -NH₂, or -OH;


R^6 and R^7 are independently -H, or $-\text{C}_{1-4}\text{alkyl}$;

R^8 is independently -H, -OH, -CN, $-\text{NR}^9\text{R}^{10}$, $-\text{C}_{1-4}\text{alkyl}$, $-\text{C}_{3-6}\text{cycloalkyl}$, $-\text{C}_{1-4}\text{heteroalkyl}$, -aryl, - $\text{C}_{1-4}\text{alkylNR}^9\text{R}^{10}$, $-(\text{CH}_2)_p\text{C}(=\text{O})\text{C}_{1-4}\text{alkyl}$, $-(\text{CH}_2)_p\text{C}(=\text{O})\text{C}_{3-6}\text{cycloalkyl}$, $-(\text{CH}_2)_p\text{C}(=\text{O})\text{C}_{1-4}\text{heteroalkyl}$, $-\text{C}(=\text{O})\text{H}$, $-(\text{CH}_2)_p\text{C}(=\text{O})\text{OR}^9$, $-\text{C}(=\text{O})(\text{CH}_2)_p\text{OR}^9$, $-(\text{CH}_2)_p\text{C}(=\text{O})\text{C}_{1-4}\text{alkylOR}^9$, $-(\text{CH}_2)_p\text{C}(=\text{O})(\text{CH}_2)_p\text{NR}^9\text{R}^{10}$, $-(\text{CH}_2)_p\text{C}(=\text{O})\text{NR}^9\text{OR}^{10}$, $-(\text{CH}_2)_p\text{CH}(\text{=NOC}_{1-4}\text{alkyl})$, $-(\text{CH}_2)_p\text{C}(=\text{NOC}_{1-4}\text{alkyl})\text{C}_{1-4}\text{alkyl}$, $-(\text{CH}_2)_p\text{-SO}_2\text{-C}_{1-4}\text{alkyl}$, $-(\text{CH}_2)_p\text{-SO}_2\text{-NR}^9\text{R}^{10}$, CONHR⁹, or $-\text{C}(=\text{R}^{11})(\text{NR}^{12}\text{R}^{12})$;


Atty Docket No. PC27820A
 Appl. No. 10/815,589
 Reply to Office action of February 12, 2007

each R^9 and R^{10} are independently -H, -C₁₋₄alkyl, -C₃₋₆cycloalkyl, -aryl, -C(=O)C₁₋₄alkyl, -C(=O)NHC₁₋₄alkyl, -C(=O)aryl, -SO₂C₁₋₄alkyl, or -SO₂NH₂;
 R^{11} is =NH, =NCN, or =CHNO₂;
 each R^{12} is independently H, or C₁₋₃alkyl;
 each m is independently an integer equal to 0, 1, or 2;
 each n is independently an integer equal to 0, or 1;
 each p is an integer equal to 0, 1, or 2; and
 at each occurrence, C₁₋₄alkyl, or C₃₋₆cycloalkyl is optionally substituted by one to three halo, hydroxyl, -CN, OC₁₋₂alkyl or aryl.

40 (new). A compound according to claim 39 which is a compound of formula IA



wherein Z is -NHC(=Q)R¹, or a compound of formula IB



wherein Z is -C(=O)NH₂.

41 (new). A compound of claim 40 wherein Q is oxygen atom.

42 (new). A compound of claim 40 wherein R¹ is C₁₋₄alkyl, optionally substituted with one, two or three fluoro or chloro.

Atty Docket No. PC27820A
Appl. No. 10/815,589
Reply to Office action of February 12, 2007

43 (new). A compound of claim 40, wherein R¹ is C₁₋₄alkyl or C₃₋₆cycloalkyl, optionally substituted with -OH, or CN.

44 (new). A compound of claim 40 wherein R¹ is -CH₃, -CHF₂, -CF₃, -CHCl₂, -CH₂CF₃, -CH₂CH₃, -CH₂CHF₂, or -CH₂CH₂F.

45 (new). A compound of 40 wherein R² and R³ are -H.

46 (new). A compound of claim 40, wherein R⁴ and R⁵ are independently -H or -F.

47 (new). The compound of claim 40, wherein R⁶ and R⁷ are -H.

48 (new). A compound of claim 40 wherein Y is -N(R⁸)-.

49 (new). A compound of claim 48 wherein R⁸ is -C(=O)(CH₂)_pOR⁹.

50 (new). A compound of claim 49 wherein R⁹ is H or C₁₋₄alkyl.

51 (new). A compound of claim 48 wherein R⁸ is -C(=O)C₁₋₄alkyl, wherein the alkyl is optionally substituted with one, two, or three OH, F, or CN.

52 (new). A compound of claim 48 wherein R⁸ is -(CH₂)_pC(=O)C₃₋₆cycloalkyl wherein the alkyl is optionally substituted with one, two, or three OH, F, or CN.

53 (new). A compound of claim 48 wherein R⁸ is -(CH₂)_pC(=O)(CH₂)_pNR⁹R¹⁰.

54 (new). A compound of claim 53 wherein R⁹ and R¹⁰ are independently H, C₁₋₄alkyl, or -C(=O)C₁₋₄alkyl.

Atty Docket No. PC27820A
Appl. No. 10/815,589
Reply to Office action of February 12, 2007

55 (new). A compound of claim 48 wherein R⁸ is -C(=O)H, -C(=O)CH₂OH, -C(=O)CH(OH)CH₂OH, -C(=O)het¹, or -C(=O)(CH₂)het².

56 (new) A compound of claim 48 wherein R⁸ is (R¹¹=)C-NR¹²R¹², wherein R¹¹ is -NH, -NCN, or -CHNO₂; and each R¹² is independently H, or C₁₋₃alkyl.

57 (new). A comopund of claim 40 wherein Y is -S-, -SO-, -SO₂-, or, -O-.

58 (new). A compound of claim 39 which is

- (1) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (2) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.- 0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (3) N-[((5S)-3-{4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (4) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxabicyclo[3.1.0]hex-6-yl]-3-oxo-1,- 3-oxazolidin-5-yl)methyl]acetamide,
- (5) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S-)-3-glycoloyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (6) 2,2-difluoro-N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3- -glycoloyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)m- ethyl]ethanethioamide,
- (7) methyl exo-(1R,5S)-6-(4-((5S)-5-[(acetylamino)m- ethyl]-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl)-3-azabicyclo[3.1.0]hexan- e-3-carboxylate,
- (8) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-formyl-3-azabic- yclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (9) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-((2S)-2,3-dihydroxypropanoyl)-3- azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetam- ide,
- (10) exo-(1R,5S)-6-(4-((5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazoli- din-3-yl)-2-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxamide,

Atty Docket No. PC27820A
Appl. No. 10/815,589
Reply to Office action of February 12, 2007

- (11) exo-(1R,5S)-6-[4-((5S)-5-{{(2,2-difluoroethanethioyl)amino]methyl}-2-oxo-- 1,3-oxazolidin-3-yl)-2-fluorophenyl]-3-azabicyclo[3.1.0]hexane-3-carboxamide,
- (12) N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (13) N-[((5S)-3-{4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (14) N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (15) N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3-glycoloyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (16) N-[((5S)-3-{4-[exo-(1R,5S)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (17) N-[((5S)-3-{4-[exo-(1R,5S)-3-glycoloyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (18) N-[((5S)-3-{4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (19) N-[((5S)-3-{4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (20) (5R)-3-{4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluoro- phenyl}-2-oxo-1,3-oxazolidine-5-carboxamide,
- (21) N-[((5S)-3-{4-[exo-(1R,5S)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (22) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-formyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (23) exo-(1R,5S)-6-(4-((5S)-5-[(propanoylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxamide,
- (24) exo-(1R,5S)-6-(4-((5S)-5-[(propanoylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-methylcarboxamide,
- (25) exo-(1R,5S)-6-(4-((5S)-5-[(propanoylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-ethylcarboxamide,

Atty Docket No. PC27820A

Appl. No. 10/815,589

Reply to Office action of February 12, 2007

- (26) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-glycoloyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (27) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-methoxyacetyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (28) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-((2S)-2,3-dihydroxypropanoyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (29) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-(2-(S)-hydroxypropanoyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (30) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-cyclopropanecarbonyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (31) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-(1-hydroxy-cyclopropanecarbonyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (32) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-(2-hydroxy-2-methylpropionoyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (33) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-(3,3,3-trifluoro-2-(S)-hydroxypropanoyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (34) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-difluoroacetyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (35) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-aminoacetyl-1-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (36) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-acetylaminoacetyl-3-aza-bicyclo-[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (37) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-(2-fluoroethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (38) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-(2-hydroxyethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (39) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-(2-cyanoethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (40) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-dimethylamino-3-azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,

Atty Docket No. PC27820A
Appl. No. 10/815,589
Reply to Office action of February 12, 2007

- (41) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]- phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (42) N-[((5S)-3-{4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (43) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]- phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarboxamide,
- (44) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarboxamide,
- (45) 2,2-difluoro-N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (46) 2,2-difluoro-N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (47) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclobutanecarboxamide,
- (48) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclobutanecarboxamide,
- (49) N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (50) N-[((5S)-3-(3,5-difluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (51) 2,2-difluoro-N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabi- cyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,
- (52) N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarboxamide,
- (53) N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarboxam- ide,
- (54) exo-(1R,5S)-6-(4-((5S)-5-[(propanoylamino)methyl]-2-oxo-1,3-oxaz- olidin-3-yl)-2,6-difluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxamide,
- (55) N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3-glycoloyl-3-azabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanamide,

Atty Docket No. PC27820A
Appl. No. 10/815,589
Reply to Office action of February 12, 2007

- (56) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]- phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]-2-hydroxyacetamide,
- (57) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]-2-hydroxyacetamide,
- (58) 2-cyano-N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (59) 2-cyano-N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (60) 2-cyano-N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3-oxido-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (61) 2-cyano-N-[((5S)-3-{3,5-difluoro-4-[exo-(1R,5S)-3,3-dioxide-3-thiabicyclo[3.1.0]hex-6- yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (62) N-[((5S)-3-(4-{exo-(1R,5S)-3-[amino(imino)methyl]-3-azabicyclo[3.1.0]hex-6- yl}-3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide,
- (63) exo-(1R,5S)-N'-cyano-6-(4-((5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl)-N-methyl-3-azabicyclo[3.1.0]hexane-3-carboximida- mide,
- (64) exo-(1R,5S)-N'-cyano-6-(4-((5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3- yl)-2-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboximid- amide, or
- (65) N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-((E)-1-{methylamino}-2-nitrovinyl)-3- azabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide:

59 (new). A method for treating bacterial infections comprising administering to a mammal being treated a pharmaceutically effective amount of the compound of claim 39.

60 (new). The method of claim 59 wherein the compound is administered parenterally, topically, rectally, or intransasally.

61 (new). The method of claim 59 wherein the compound is administered orally.

Atty Docket No. PC27820A
Appl. No. 10/815,589
Reply to Office action of February 12, 2007

62 (new). The methos of claim 59 wherein parenteral administration is subcutaneous, intravenous, intramuscular, intradermal, intrathecal, intraocular, intraventricular injection.

63 (new). The method of claim 59 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

64 (new). The method of claim 59 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

65 (new). The method of claim 59 wherein said infection is skin infection.

66 (new). The method of claim 59 wherein the infection is eye infection.

67 (new). The method of claim 59 wherein said mammal is human.

68 (new). The methos of claim 59 wherein said mammal is an animal.

69 (new). A pharmaceutical composition comprising a compound of claim 39 and a pharmaceutically acceptable carrier.